JOURNAL OF THE CZECH PHARMACEUTICAL SOCIETY AND THE SLOVAK PHARMACEUTICAL SOCIETY

Čes. slov. farm. 2025, 74(1):E11-E16 | DOI: 10.36290/csf.2025.001

Covalent drugs

PharmDr. Marta Kučerová, Ph.D.
Univerzita Karlova, Farmaceutická fakulta v Hradci Králové, Katedra farmaceutické chemie
a farmaceutické analýzy, Hradec Králové

Covalent drugs are substances capable of forming a reversible or an irreversible covalent bond with a macromolecular target in the body. Despite the risk of adverse reactions in the organism, the design of such agents has become a trend over the last two decades. Drugs acting by covalent mechanisms from different indication groups are summarized in this article and possibly supported with a reference to the crystallographic structure in the Protein Data Bank. The advantages and the disadvantages of using covalent drugs are also discussed.

Keywords: covalent bond, targeted covalent inhibitors

Accepted: March 3, 2025; Published: March 20, 2025  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Kučerová M. Covalent drugs. Čes. slov. farm. 2025;74(1):E11-16. doi: 10.36290/csf.2025.001.

Zobrazit celý článek

Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • PDF will be unlocked 20.3.2026

    References

    1. Kučerová M. Binding forces: types of drug interactions with molecular targets in organism. Klin Farmakol Farm. 2024;38(3):118-122. doi:10.36290/far.2024.019. Go to original source...
    2. Vasudevan A, Argiriadi MA, Baranczak A, et al. Chapter One - Covalent binders in drug discovery. In: Witty DR, Cox B, editors. Progress in Medicinal Chemistry. Elsevier; 2019:1-62. Go to original source...
    3. Li QK, Chen Q, Klauser PC, et al. Developing covalent protein drugs via proximity-enabled reactive therapeutics. Cell. Jul 2020;182(1):85-97. doi:10.1016/j.cell.2020.05.028. Go to original source... Go to PubMed...
    4. Singh J, Petter RC, Baillie TA, Whitty A. The resurgence of covalent drugs. Nat Rev Drug Discov. Apr 2011;10(4):307-317. doi:10.1038/nrd3410. Go to original source... Go to PubMed...
    5. Chatterjee P, Botello-Smith WM, Zhang H, et al. Can relative binding free energy predict selectivity of reversible covalent inhibitors? J Am Chem Soc. 2017;139(49):17945-17952. doi:10.1021/jacs.7b08938. Go to original source... Go to PubMed...
    6. Scarpino A, Ferenczy GG, Keseru GM. Covalent docking in drug discovery: scope and limitations. Curr Pharm Design. 2020;26(44):5684-5699. doi:10.2174/1381612824999201105164942. Go to original source... Go to PubMed...
    7. Gehringer M. Covalent inhibitors: back on track? Future Med Chem. 2020;12(15):1363-1368. doi:10.4155/fmc-2020-0118. Go to original source... Go to PubMed...
    8. Potashman MH, Duggan ME. Covalent modifiers: an orthogonal approach to drug design. J Med Chem. 2009;52(5):1231-1246. doi:10.1021/jm8008597. Go to original source... Go to PubMed...
    9. Bauer RA. Covalent inhibitors in drug discovery: from accidental discoveries to avoided liabilities and designed therapies. Drug Discov Today. 2015;20(9):1061-1073. doi:10.1016/j.drudis.2015.05.005. Go to original source... Go to PubMed...
    10. Abrányi-Balogh P, Petri L, Imre T, et al. A road map for prioritizing warheads for cysteine targeting covalent inhibitors. Eur J Med Chem. Dec 2018;160:94-107. doi:10.1016/j.ejmech.2018.10.010. Go to original source... Go to PubMed...
    11. Dalton SE, Campos S. Covalent small molecules as enabling platforms for drug discovery. ChemBioChem. 2020;21(8):1080-1100. doi:10.1002/cbic.201900674. Go to original source... Go to PubMed...
    12. Boike L, Henning NJ, Nomura DK. Advances in covalent drug discovery. Nat Rev Drug Discov. 2022;21(12):881-898. doi:10.1038/s41573-022-00542-z.  Go to original source... Go to PubMed...
    13. Du JW, Yan X, Liu ZH, et al. cBinderDB: a covalent binding agent database. Bioinformatics. 2017;33(8):1258-1260. doi:10.1093/bioinformatics/btw801. Go to original source... Go to PubMed...
    14. LoPachin RM, Gavin T, DeCaprio A, Barber DS. Application of the hard and soft, acids and bases (HSAB) theory to toxicant-target interactions. Chem Res Toxicol. 2012;25(2):239-251. doi:10.1021/tx2003257. Go to original source... Go to PubMed...
    15. Sutanto F, Konstantinidou M, Dömling A. Covalent inhibitors: a rational approach to drug discovery. RSC Med Chem. 2020;11(8):876-884. doi:10.1039/d0md00154f. Go to original source... Go to PubMed...
    16. Ábrányi-Balogh P, Keserű GM. Warheads for designing covalent inhibitors and chemical probes. Advances in Chemical Proteomics. 2021:47-73. Go to original source...
    17. Gehringer M, Laufer SA. Emerging and re-emerging warheads for targeted covalent inhibitors: applications in medicinal chemistry and chemical biology. J Med Chem. 2019;62(12):5673-5724. doi:10.1021/acs.jmedchem.8b01153. Go to original source... Go to PubMed...
    18. Robertson JG. Mechanistic basis of enzyme-targeted drugs. Biochemistry. 2005;44(15):5561-5571. doi:10.1021/bi050247e. Go to original source... Go to PubMed...
    19. Burley SK, Bhikadiya C, Bi CX, et al. RCSB Protein Data Bank (RCSB.org): delivery of experimentally-determined PDB structures alongside one million computed structure models of proteins from artificial intelligence/machine learning. Nucleic Acids Res. 2023;51(D1):D488-D508. doi:10.1093/nar/gkac1077. Go to original source... Go to PubMed...
    20. Baillie TA. Approaches to mitigate the risk of serious adverse reactions in covalent drug design. Expert Opin Drug Discov. 2021;16(3):275-287. doi:10.1080/17460441.2021.1832079. Go to original source... Go to PubMed...
    21. Zhou Y, Yu H, Vind AC, et al. Rational design of covalent kinase inhibitors by an integrated computational workflow (Kin-Cov). J Med Chem. 2023;66(11):7405-7420. doi:10.1021/acs.jmedchem.3c00088. Go to original source... Go to PubMed...
    22. Guo XK, Zhang YK. CovBinderInPDB: a structure-based covalent binder eatabase. J Chem Inf Model. 2022;62(23):6057-6068. doi:10.1021/acs.jcim.2c01216. Go to original source... Go to PubMed...
    23. Gao MJ, Moumbock AFA, Qaseem A, Xu QQ, Günther S. CovPDB: a high-resolution coverage of the covalent protein-ligand interactome. Nucleic Acids Res. 2022;50(D1):D445-D450. doi:10.1093/nar/gkab868. Go to original source... Go to PubMed...

    Return to the content


    Czech and Slovak Pharmacy

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.